News and Events – June 2007
PUBLICATIONS
Lim A, Leow L, Huckabee ML, Frampton C, Anderson T (in press). A pilot study of respiration and swallowing integration in Parkinson’s disease: “on” and “off” levodopa. Dysphagia.
CONFERENCES
Phil Bones attended a conference comprising four topical meetings of The Optical Society of America (OSA) on 18-20th June 2007. Phil reports that the Signal Recovery and Synthesis meeting, while not specifically medical, did have a number of papers related to medical imaging. Phil also took the opportunity after the conference to go north to Whistler, where he hiked, mountain-biked and skiied (yes, Whistler has some skiing right through to the end of July).
Bones PJ, Maclaren JR. Artifact reduction in magnetic resonance imaging. In Signal Recovery and Synthesis. The Optical Society of America, Washington, DC, 2007, CD-ROM SMA6.
Bones PJ, Wu B, Millane RP, Watts R. Support constraint in 3D magnetic resonance imaging. In Signal Recovery and Synthesis (Postdeadline Papers). The Optical Society of America, Washington, DC, 2007, SMD6.
Tim Anderson presented a poster at the 11th International Congress of Parkinson’s Disease and Movement Disorders in Istanbul, Turkey (3-7 June, 2007).
Leow LP, Huckabee M-L, Anderson TJ. Swallowing efficiency in Parkinson’s disease. Proceeding of the 11th International Congress of Parkinson’s Disease and Movement Disorders. Istanbul, Turkey, 3-7 June, 2007.
PEOPLE AT VDVI
Ai Leen Choo - MSc student, Department of Communication Disorders, University of Canterbury, under the supervision of Maggie-Lee Huckabee, Michael Robb, and John Dalrymple-Alford. Project title: Bereitschaftspotential (BP) in individuals who stutter during speech tasks.
OTHER NEWS
Neurotechnology Industry Organization (NIO)
The Van der Veer Institute has been accepted as a member of the Founder’s Circle of the recently formed Neurotechnology Industry Organisation (www.neurotechindustry.org). NIO is a non-profit trade association that represents companies involved in neuroscience (neuropharmaceuticals, neurodevices and neurodiagnostics), academic neuroscience research centers, and brain-illness advocacy groups across the United States and throughout the world. It was formed to provide a unified voice for the commercial neuroscience community and advocates for its member organizations on a range of issues related to neurotechnology research and business development. NIO’s mission is to accelerate cures for brain and nervous system diseases by:
* Promoting the industry’s progress & contributions to quality of life
* Advocating the industry’s position to regulators & elected officials
* Providing effective business development services to members